人類結核病疫苗市場按類型、年齡層、分銷管道和地區分類

2025 年全球人類結核病疫苗市場規模估計為 6,810 萬美元，預計到 2032 年將達到 1.024 億美元，2025 年至 2032 年的複合年成長率為 6.0%。

數字。 2025 年人類結核病疫苗市場佔有率（按地區分類）

儘管結核病是一種可治療和預防的疾病，但它仍然是全球十大死亡原因之一。目前，唯一廣泛使用的結核病疫苗是卡介苗（BCG）疫苗，其保護作用有限，且僅建議兒童使用。迫切需要開發新的有效疫苗來遏制全球結核病負擔。幾種候選疫苗目前正在進行針對結核菌生命週期不同階段的臨床試驗。一種能夠持久預防肺結核疾病和傳播的疫苗可能會在消滅這種古老病原體的努力中發揮重要作用。

市場動態

全球人類結核病疫苗市場主要受全球持續存在的結核病負擔所推動。 2025年10月29日，根據世界衛生組織的數據，2025年將總合125萬人死於結核病。結核病在被感染疾病（COVID-19）取代三年後，可能已重新成為世界最大的單一感染疾病死因。對改善診斷方法和疫苗的需求促使國際衛生組織投入大量資金進行結核病疫苗的研究和開發。目前，已有超過15種候選疫苗處於不同階段的臨床試驗。然而，高昂的開發成本和監管障礙仍然是挑戰。科學家正在探索 mRNA 平台等新技術，以提高結核病疫苗的有效性、安全性和製造的簡易性。由於印度和中國等國結核病發生率高，亞太地區是最大的市場。開發有效的疫苗有可能遏制疾病傳播並為負擔過重的衛生系統節省大量資金。

研究的主要特點

本報告對全球人類結核病疫苗市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。

它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。

它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。

全球人類結核病疫苗市場的主要企業是根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行分析的。

研究涉及的主要企業包括葛蘭素史克公司 (GSK plc.)、印度血清研究所 (Serum Institute of India Pvt.)。 Ltd.、Valneva SE、Archivel Farma、BIOFABRI（Zendal）、日本 BCG 實驗室、CSL Seqirus、GreenSignal Bio Pharma Private Limited (GSBPL)、AJ Vaccines A/S、Taj Pharmaceuticals Ltd.、Merck & Co., Inc.、Bharat BIoTechNderTech。

本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。

全球人類結核病疫苗市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。

相關人員將透過全球人類結核病疫苗市場分析中使用的各種策略矩陣來做出決策。

目錄

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章市場動態、法規與趨勢分析

• 市場動態
• 影響分析
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購情景
• 流行病學

4. 人類結核病疫苗市場（按類型），2020 年至 2032 年

• 介紹
• 減毒活疫苗
• 不活化疫苗
• 其他

5. 人類結核病疫苗市場，依年齡層，2020 年至 2032 年

• 介紹
• 孩子們
• 成人

6. 2020 年至 2032 年按分銷管道分類的人類結核病疫苗市場

• 介紹
• 私人的
• 公共

7. 人類結核病疫苗市場，依地區、價值，2020 年至 2032 年

• 介紹
• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第8章 競爭格局

• GSK plc.
• Serum Institute of India Pvt. Ltd.
• Valneva SE
• Archivel Farma
• BIOFABRI（Zendal）
• Japan BCG Laboratory
• CSL Seqirus
• GreenSignal Bio Pharma Private Limited（GSBPL）
• AJ Vaccines A/S
• Taj Pharmaceuticals Ltd.
• Merck & Co., Inc.
• Bharat BIoTech
• Moderna, Inc.
• BioNTech SE

第 9 章分析師建議

• 興衰
• 一致的機會地圖

第10章參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global Human Tuberculosis Vaccine Market is estimated to be valued at USD 68.1 Mn in 2025 and is expected to reach USD 102.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Figure. Human Tuberculosis Vaccine Market Share (%), By Region 2025

Tuberculosis remains one of the top 10 causes of death worldwide, despite being a curable and preventable disease. Currently, the only widely used TB vaccine is the Bacille Calmette-Guerin (BCG) vaccine, which provides limited protection and is only recommended for children. There is an urgent need for new, effective vaccines to control the global TB burden. Several candidate vaccines are in clinical trials, targeting different stages of the Mycobacterium tuberculosis lifecycle. Vaccines that provide lasting protection against pulmonary TB disease and transmission could be a game changer in the effort to eliminate this ancient pathogen.

Market Dynamics:

The global human tuberculosis vaccine market is primarily driven by the persistent burden of TB disease worldwide. On October 29, 2025, according to the WHO, a total of 1.25 million people died from tuberculosis (TB) in 2025. Worldwide, TB has probably returned to being the world's leading cause of death from a single infectious agent, following three years in which it was replaced by coronavirus disease (COVID-19). The need for improved diagnostics and vaccines has spurred heavy investments from global health organizations into TB vaccine R&D. Over 15 vaccine candidates are currently in clinical trials of different phases. However, high development costs and regulatory hurdles pose challenges. Scientists are exploring new technologies like mRNA platforms to improve the efficacy, safety, and ease of manufacture of tuberculosis vaccines. Asia Pacific is the largest market due to high TB prevalence in countries like India and China. Developing an effective vaccine could potentially curb disease transmission and generate substantial savings for overburdened healthcare systems.

Key Features of the Study:

This report provides in-depth analysis of the global human tuberculosis vaccine market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global human tuberculosis vaccine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GSK plc., Serum Institute of India Pvt. Ltd., Valneva SE, Archivel Farma, BIOFABRI (Zendal), Japan BCG Laboratory, CSL Seqirus, GreenSignal Bio Pharma Private Limited (GSBPL), AJ Vaccines A/S, Taj Pharmaceuticals Ltd., Merck & Co., Inc., Bharat Biotech, Moderna, Inc., and BioNTech SE

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global human tuberculosis vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human tuberculosis vaccine market

Market Segmentation

• By Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Live attenuated vaccine
  • Inactivated
  • Others
• By Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Pediatrics
  • Adults
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Private
  • Public
• By Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • GSK plc.
  • Serum Institute of India Pvt. Ltd.
  • Valneva SE
  • Archivel Farma
  • BIOFABRI (Zendal)
  • Japan BCG Laboratory
  • CSL Seqirus
  • GreenSignal Bio Pharma Private Limited (GSBPL)
  • AJ Vaccines A/S
  • Taj Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Bharat Biotech
  • Moderna, Inc.
  • BioNTech SE

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Human Tuberculosis Vaccine Market, By Type
  • Human Tuberculosis Vaccine Market, By Age Group
  • Human Tuberculosis Vaccine Market, By Distribution Channel
  • Human Tuberculosis Vaccine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Epidemiology

4. Human Tuberculosis Vaccine Market, By Type, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Live attenuated vaccine
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Inactivated
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Human Tuberculosis Vaccine Market, By Age Group, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pediatrics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Human Tuberculosis Vaccine Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Human Tuberculosis Vaccine Market, By Region, 2020 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

8. Competitive Landscape

• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Serum Institute of India Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Valneva SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Archivel Farma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BIOFABRI (Zendal)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Japan BCG Laboratory
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• CSL Seqirus
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GreenSignal Bio Pharma Private Limited (GSBPL)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AJ Vaccines A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Taj Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co., Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bharat Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Moderna, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BioNTech SE
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

9. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. References and Research Methodology

• References
• Research Methodology
• About us